Abstract YO13
Case summary
Background: Immunoglobulin G4 (IgG4)-related disease is a rare immune-mediated fibroinflammatory condition, characterized by infiltration of IgG4 positive plasma cells and storiform fibrosis. The clinical presentation included fibrosis of affected organs and pseudotumor formation occasionally mimic malignancy.
Aims: To present a case of IgG4-related kidney disease mimicking renal cell carcinoma
Method: Case report
Result: 53-year-old male with an unremarkable previous medical history presented with painless gross hematuria, fever and anemic symptom for 3 months. Laboratory tests showed microcytic anemia, normal creatinine levels and numerous white blood cells in urine. CT chest and abdomen revealed an infiltrative heterogenous hypoenhancing lesion at right kidney size 7.5 x7.9 x8.5cm, a hypoenhancing lesion in hepatic segment IVa/VIII size 6.8x3.8 cm, diffuse intraabdominal lymph node enlargement up to 1.8 cm and multiple lung nodules. The initial clinical and radiologic findings were highly suggestive of malignancy. The differential diagnosis is renal cell carcinoma and lymphoma. Liver biopsy was performed and shown chronic inflammation and fibrosis. Subsequently renal biopsy was done and revealed chronic interstitial nephritis, focal interstitial fibrosis and prominent plasma cell infiltration. Immunohistochemistry from renal biopsy revealed positive for CD20, CD3, CD38, CD138, IgG (210 cells/HPF) and IgG4/IgG-positive cell ratio was 54%. In situ hybridization for kappa and lambda light chain showed polyclonal plasma cell with kappa to lambda ratio of 4:1. Serum IgG4 level was more than 5,840 mg/dL. These findings made diagnosis of IgG4 related kidney disease. Prednisolone 60 mg/day was given and gradually reduced to 10 mg five months thereafter. After 3 months of therapy, a follow-up CT scan showed decrease size of right renal mass to 6.1 x7.3 x6.2 cm, nearly complete resolved of liver lesion and some prior pulmonary nodules.
Conclusion: IgG4 related kidney disease can present with pseudotumor and can be misdiagnosed as a malignant tumor. Awareness of this condition and proper investigation including histopathology and serum IgG4 level should be considered in case of highly suggestive patient.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
51P - Enhancing the anti-breast tumour activity of STING through a novel sting transcriptional regulator
Presenter: Hanchu Xiong
Session: Poster display session
Resources:
Abstract
52P - Reverse Warburg effect-related mitochondrial activity and 18F-FDG uptake in invasive ductal carcinoma
Presenter: Byung Wook Choi
Session: Poster display session
Resources:
Abstract
53P - Phase II study of atorvastatin in combination with radiotherapy and temozolomide in patients with glioblastoma (ART): Final analysis report
Presenter: Abdullah Altwairgi
Session: Poster display session
Resources:
Abstract
54P - Association between Parkinson’s disease and brain tumours: A nationwide population-based cohort study
Presenter: Joo-hyun Park
Session: Poster display session
Resources:
Abstract
55P - Toxicity profiles of treatment with modern fractionated radiotherapy, contemporary stereotactic radiosurgery, or transsphenoidal surgery in non-functioning pituitary macroadenoma
Presenter: Kevin Sheng-Po Yuan
Session: Poster display session
Resources:
Abstract
56P - Hippocampal avoidance in WBRT for metastases: Comparative neurocognitive and dosimetric assessment
Presenter: Vibhay Pareek
Session: Poster display session
Resources:
Abstract
57P - Multidisciplinary brain metastasis clinic: Is it effective and worthwhile?
Presenter: Annu Rajpurohit
Session: Poster display session
Resources:
Abstract
58P - Functional status as a determinant prognostic factor for overall survival in adult patients with medulloblastoma treated with chemotherapy and radiotherapy
Presenter: Juan Ayala Alvarez
Session: Poster display session
Resources:
Abstract
59P - Pattern of care in high-grade gliomas after recurrence
Presenter: Nandini Menon
Session: Poster display session
Resources:
Abstract
60P - Five fractions plus “SRS” boost combined with temozolamide for newly diagnosed and recurrent glioblastoma multiforme (GBM)
Presenter: Azhar Rashid
Session: Poster display session
Resources:
Abstract